Fibroblasts from distinct pancreatic diseases exhibit distinct genetic profiles and gene expression patterns, highlighting the importance of using disease-specific fibroblasts for research. The study also identifies a potential biomarker for distinguishing between pancreatic cancer and chronic pancreatitis.
Scientists have identified a peptide from the foot-and-mouth-disease virus that targets a protein on pancreatic cancer cells, allowing for highly potent drug delivery and complete tumour killing in mice. The research offers a promising new approach to treating pancreatic cancer with limited side effects.
UK scientists have discovered a potential new treatment strategy for pancreatic cancer by targeting energy production in cells, leading to an irreversible build-up of calcium and cell death. The approach involves inhibiting a specific enzyme called PKM2, which fuels calcium pumps on the cell surface.
A urine test that measures specific proteins found in urine can detect early-stage pancreatic cancer with nearly 95% accuracy. The UroPanc clinical study aims to validate this biomarker in a clinical setting, with the potential to develop a standardized urine test for clinicians to use as a diagnostic aid.
Researchers have identified a key protein involved in pancreatic cancer cell growth and found an antibody therapy that targets it, reducing tumour growth and increasing survival time in mice. The treatment combines the antibody with gemcitabine and achieves up to a sixfold increase in survival time compared to controls.
Seven cutting-edge research projects have been awarded grants to tackle pancreatic cancer, with a focus on early diagnosis, potential new treatments, and understanding immunotherapy's limitations.
Seven new grants will support studies on personalized treatments, non-invasive cancer cell killing, and early tumor detection using advanced imaging techniques. These projects aim to improve survival statistics for pancreatic cancer patients and accelerate research progress.
A new study confirms PAK4's role in enabling pancreatic cancer cells to grow and spread, highlighting potential new targets for therapy. Researchers found a close relationship between PAK4 and the phosphoinositide 3-kinase pathway, which could lead to combination therapies targeting both.
The UK Pancreatic Cancer Research Fund has awarded £9 million in grants to five promising research projects aimed at developing new treatments and diagnostic tools for pancreatic cancer. These projects focus on improving clinical trials, investigating innovative therapies, and understanding the genetic causes of chromosomal instability.
Researchers at Queen Mary University of London have developed a modified flu virus that can re-sensitize resistant pancreatic cancer cells to chemotherapy. The virus enhances the efficacy of the drug by preventing cancer cells from repairing themselves, leading to increased cell killing with lower doses.
The charity has funded 40 research projects worth over £6 million, including grants for innovative treatments and personalised medicine approaches. Six new projects aim to develop imaging techniques, epigenetic biomarkers, and targeted therapies to improve patient outcomes.
The UK's first national tissue bank aims to develop new treatments and improve patient outcomes for pancreatic cancer. The Tissue Bank will store high-quality samples from consenting patients, enabling researchers to test ideas and validate their research more effectively.
Researchers at Barts Cancer Institute have identified a three-protein 'signature' in urine that can accurately detect early-stage pancreatic cancer with over 90% accuracy. This discovery could lead to a simple and inexpensive test for high-risk individuals, improving survival rates.
A study led by Dr Yaohe Wang at Barts Cancer Institute found that arming a modified virus called Vaccinia with a specific gene enhanced its effectiveness against pancreatic cancer. In mice, the armed virus was more effective in killing tumors and preventing regrowth compared to an unarmed version.
The UK's Pancreatic Cancer Research Fund has invested £1.2 million in seven new projects aimed at developing new treatments for pancreatic cancer. The projects will focus on targeting the energy supply of cancer cells and improving chemotherapy absorption, among other areas.
Researchers from Imperial College London have discovered that blocking Hhat slows pancreatic cancer growth by preventing Hedgehog from stimulating nearby cells. The study found that genetic techniques could prevent the process from starting in the first place, leading to reduced cancer cell growth and ability to spread.